Impact of ACE I gene insertion/deletion, A-240T polymorphisms and the renin-angiotensin-aldosterone system on COVID-19 disease.
ACE-polymorphism
COVID-19
Inflammation
Renin–angiotensin–aldosteron-system (RAAS)
SARS-CoV2
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
10 Jan 2024
10 Jan 2024
Historique:
received:
07
06
2023
accepted:
30
12
2023
medline:
11
1
2024
pubmed:
11
1
2024
entrez:
10
1
2024
Statut:
epublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic is driven by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which has led to an enormous burden on patient morbidity and mortality. The renin-angiotensin-aldosterone system (RAAS) plays a significant role in various pulmonary diseases. Since SARS-CoV-2 utilizes the angiotensin-converting enzyme (ACE)2 receptor to exert its virulence and pathogenicity, the RAAS is of particular importance in COVID 19. Our preliminary study investigates retrospectively the influence of selected ACE-polymorphisms (I/D location at intron 16 in the B-coding sequence (rs4646994) and A-240T (rs 4291) at the A-promoter) as well as ACE1 and ACE2 serum levels on disease severity and the inflammatory response in inpatients and outpatients with COVID-19. Our study included 96 outpatients and 88 inpatients (65.9% male, mean age 60 years) with COVID-19 from April to December 2020 in four locations in Germany. Of the hospitalized patients, 88.6% participants were moderately ill (n = 78, 64% male, median age 60 years), and 11.4% participants were severely ill or deceased (n = 10, 90% male, median age 71 years). We found no polymorphism-related difference in disease, in age distribution, time to hospitalization and time of hospitalization for the inpatient group. ACE1 serum levels were significantly increased in the DD compared to the II polymorphism and in the TT compared to the AA polymorphism. There was no significant difference in ACE 1 serum levels l between moderately ill and severely ill patients. However, participants requiring oxygen supplementation had significantly elevated ACE1 levels compared to participants not requiring oxygen, with no difference in ACE2 levels whereas females had significantly higher ACE2 levels. Although there were no differences in the distribution of ACE polymorphisms in disease severity, we found increased proinflammatory regulation of the RAAS in patients with oxygen demand and increased serum ACE2 levels in women, indicating a possible enhanced anti-inflammatory immune response. PreBiSeCov: German Clinical Trials Register, DRKS-ID: DRKS00021591, Registered on 27th April 2020.
Sections du résumé
BACKGROUND
BACKGROUND
The coronavirus disease 2019 (COVID-19) pandemic is driven by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which has led to an enormous burden on patient morbidity and mortality. The renin-angiotensin-aldosterone system (RAAS) plays a significant role in various pulmonary diseases. Since SARS-CoV-2 utilizes the angiotensin-converting enzyme (ACE)2 receptor to exert its virulence and pathogenicity, the RAAS is of particular importance in COVID 19.
METHODS
METHODS
Our preliminary study investigates retrospectively the influence of selected ACE-polymorphisms (I/D location at intron 16 in the B-coding sequence (rs4646994) and A-240T (rs 4291) at the A-promoter) as well as ACE1 and ACE2 serum levels on disease severity and the inflammatory response in inpatients and outpatients with COVID-19.
RESULTS
RESULTS
Our study included 96 outpatients and 88 inpatients (65.9% male, mean age 60 years) with COVID-19 from April to December 2020 in four locations in Germany. Of the hospitalized patients, 88.6% participants were moderately ill (n = 78, 64% male, median age 60 years), and 11.4% participants were severely ill or deceased (n = 10, 90% male, median age 71 years). We found no polymorphism-related difference in disease, in age distribution, time to hospitalization and time of hospitalization for the inpatient group. ACE1 serum levels were significantly increased in the DD compared to the II polymorphism and in the TT compared to the AA polymorphism. There was no significant difference in ACE 1 serum levels l between moderately ill and severely ill patients. However, participants requiring oxygen supplementation had significantly elevated ACE1 levels compared to participants not requiring oxygen, with no difference in ACE2 levels whereas females had significantly higher ACE2 levels.
CONCLUSIONS
CONCLUSIONS
Although there were no differences in the distribution of ACE polymorphisms in disease severity, we found increased proinflammatory regulation of the RAAS in patients with oxygen demand and increased serum ACE2 levels in women, indicating a possible enhanced anti-inflammatory immune response.
CLINICAL TRIAL REGISTRATION
BACKGROUND
PreBiSeCov: German Clinical Trials Register, DRKS-ID: DRKS00021591, Registered on 27th April 2020.
Identifiants
pubmed: 38200555
doi: 10.1186/s12985-023-02283-w
pii: 10.1186/s12985-023-02283-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15Subventions
Organisme : Sanitätsakademie der Bundeswehr, Abteilung E
ID : SoFo 30K4
Organisme : Sanitätsakademie der Bundeswehr, Abteilung E
ID : SoFo 30K4
Organisme : Sanitätsakademie der Bundeswehr, Abteilung E
ID : SoFo 30K4
Organisme : Sanitätsakademie der Bundeswehr, Abteilung E
ID : SoFo 30K4
Organisme : Sanitätsakademie der Bundeswehr, Abteilung E
ID : SoFo 30K4
Organisme : Sanitätsakademie der Bundeswehr, Abteilung E
ID : SoFo 30K4
Organisme : Sanitätsakademie der Bundeswehr, Abteilung E
ID : SoFo 30K4
Investigateurs
Ullrich Baumgarten
(U)
Tobias Wageloehner
(T)
Nino Neumann
(N)
Annette Mueller
(A)
Rico Mueller
(R)
Jan Philip Krueger
(JP)
Alena Borchert
(A)
Felix Weinreich
(F)
Franziska Keidel
(F)
Maria Koch
(M)
Meike Schüßler
(M)
Informations de copyright
© 2024. The Author(s).
Références
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
pubmed: 31986264
pmcid: 7159299
doi: 10.1016/S0140-6736(20)30183-5
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.
pubmed: 32142651
pmcid: 7102627
doi: 10.1016/j.cell.2020.02.052
Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9(1):45.
pubmed: 32345362
pmcid: 7186534
doi: 10.1186/s40249-020-00662-x
Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185–92.
pubmed: 32170560
pmcid: 7088738
doi: 10.1007/s11684-020-0754-0
Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007;212(1):1–11.
pubmed: 17464936
pmcid: 7167724
doi: 10.1002/path.2162
Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7.
pubmed: 15141377
pmcid: 7167720
doi: 10.1002/path.1570
Narula S, Yusuf S, Chong M, Ramasundarahettige C, Rangarajan S, Bangdiwala SI, et al. Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. Lancet. 2020;396(10256):968–76.
pubmed: 33010842
pmcid: 7529405
doi: 10.1016/S0140-6736(20)31964-4
Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020;11(1):53.
pubmed: 32948238
pmcid: 7498997
doi: 10.1186/s13293-020-00330-7
Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767–72.
pubmed: 32304745
pmcid: 7159868
doi: 10.1016/j.cmi.2020.04.012
Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem. 2005;280(47):39353–62.
pubmed: 16166094
doi: 10.1074/jbc.M508914200
Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axis. Exp Physiol. 2008;93(5):519–27.
pubmed: 18310257
doi: 10.1113/expphysiol.2008.042002
Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. Int J Hypertens. 2012;2012: 307315.
pubmed: 22121476
doi: 10.1155/2012/307315
Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res. 2017;125(Pt A):21–38.
pubmed: 28619367
pmcid: 5607101
doi: 10.1016/j.phrs.2017.06.005
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4.
pubmed: 14647384
pmcid: 7095016
doi: 10.1038/nature02145
Tomita H, Ina Y, Sugiura Y, Sato S, Kawaguchi H, Morishita M, et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med. 1997;156(1):255–9.
pubmed: 9230757
doi: 10.1164/ajrccm.156.1.9612011
Specks U, Martin WJ 2nd, Rohrbach MS. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am Rev Respir Dis. 1990;141(1):117–23.
pubmed: 2153351
doi: 10.1164/ajrccm/141.1.117
Orte C, Polak JM, Haworth SG, Yacoub MH, Morrell NW. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol. 2000;192(3):379–84.
pubmed: 11054722
doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q
Verma S, Abbas M, Verma S, Khan FH, Raza ST, Siddiqi Z, et al. Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients. Infect Genet Evol. 2021;91: 104801.
pubmed: 33676010
pmcid: 7929788
doi: 10.1016/j.meegid.2021.104801
Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? Int J Mol Sci. 2020;21(10):3474.
pubmed: 32423094
pmcid: 7278991
doi: 10.3390/ijms21103474
Suryamohan K, Diwanji D, Stawiski EW, Gupta R, Miersch S, Liu J, et al. Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Commun Biol. 2021;4(1):475.
pubmed: 33846513
pmcid: 8041869
doi: 10.1038/s42003-021-02030-3
Delanghe JR, Speeckaert MM, De Buyzere ML. COVID-19 infections are also affected by human ACE1 D/I polymorphism. Clin Chem Lab Med. 2020;58(7):1125–6.
pubmed: 32286246
doi: 10.1515/cclm-2020-0425
Zhu X, Bouzekri N, Southam L, Cooper RS, Adeyemo A, McKenzie CA, et al. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet. 2001;68(5):1139–48.
pubmed: 11283791
pmcid: 1226095
doi: 10.1086/320104
Firouzabadi N, Tajik N, Shafiei M, Ebrahimi SA, Bakhshandeh H. Interaction of A-240T and A2350G related genotypes of angiotensin-converting enzyme (ACE) is associated with decreased serum ACE activity and blood pressure in a healthy Iranian population. Eur J Pharmacol. 2011;668(1–2):241–7.
pubmed: 21810419
doi: 10.1016/j.ejphar.2011.07.023
Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet. 1996;58(6):1268–78.
pubmed: 8651305
pmcid: 1915072
da Agostini L, Cunha WR, Silva NNT, Melo AS, Moreira LB, Almeida TC, et al. Angiotensin-converting enzyme gene (ACE) polymorphisms are associated with dysregulation of biochemical parameters in hypertensive patients. Mol Biol Rep. 2023;50(2):1487–97.
pubmed: 36507965
doi: 10.1007/s11033-022-08128-z
Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY). 2020;12(11):10087–98.
pubmed: 32501810
doi: 10.18632/aging.103415
Zobel CM, Wenzel W, Kruger JP, Baumgarten U, Wagelohner T, Neumann N, et al. Serum interleukin-6, procalcitonin, and C-reactive protein at hospital admission can identify patients at low risk for severe COVID-19 progression. Front Microbiol. 2023;14:1256210.
pubmed: 37937220
pmcid: 10626435
doi: 10.3389/fmicb.2023.1256210
Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-e7.
Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility. Clin Infect Dis. 2021;73(2):328–31.
pubmed: 32750119
doi: 10.1093/cid/ciaa1150
Martens CP, Van Mol P, Wauters J, Wauters E, Gangnus T, Noppen B, et al. Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19. EBioMedicine. 2022;83: 104195.
pubmed: 35939907
pmcid: 9352453
doi: 10.1016/j.ebiom.2022.104195
Bekassy Z, Lopatko Fagerstrom I, Bader M, Karpman D. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation. Nat Rev Immunol. 2022;22(7):411–28.
pubmed: 34759348
doi: 10.1038/s41577-021-00634-8
Carvalho PR, Sirois P, Fernandes PD. The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. Peptides. 2021;135: 170428.
pubmed: 33065209
doi: 10.1016/j.peptides.2020.170428
Shibeeb S, Khan A. ABO blood group association and COVID-19. COVID-19 susceptibility and severity: a review. Hematol Transfus Cell Ther. 2022;44(1):70–5.
pubmed: 34541459
doi: 10.1016/j.htct.2021.07.006
Gomez J, Albaiceta GM, Garcia-Clemente M, Lopez-Larrea C, Amado-Rodriguez L, Lopez-Alonso I, et al. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene. 2020;762: 145102.
pubmed: 32882331
pmcid: 7456966
doi: 10.1016/j.gene.2020.145102
Mohlendick B, Schonfelder K, Breuckmann K, Elsner C, Babel N, Balfanz P, et al. ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19. Pharmacogenet Genom. 2021;31(8):165–71.
doi: 10.1097/FPC.0000000000000436
Morimoto S, Okaishi K, Onishi M, Katsuya T, Yang J, Okuro M, et al. Deletion allele of the angiotensin-converting enzyme gene as a risk factor for pneumonia in elderly patients. Am J Med. 2002;112(2):89–94.
pubmed: 11835945
doi: 10.1016/S0002-9343(01)01071-3
van de Garde EM, Endeman H, Deneer VH, Biesma DH, Sayed-Tabatabaei FA, Ruven HJ, et al. Angiotensin-converting enzyme insertion/deletion polymorphism and risk and outcome of pneumonia. Chest. 2008;133(1):220–5.
pubmed: 17908703
doi: 10.1378/chest.07-1400
Pontremoli R, Sofia A, Tirotta A, Ravera M, Nicolella C, Viazzi F, et al. The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol. 1996;7(12):2550–8.
pubmed: 8989733
doi: 10.1681/ASN.V7122550
Avanoglu Guler A, Tombul N, Aysert Yildiz P, Ozger HS, Hizel K, Gulbahar O, et al. The assessment of serum ACE activity in COVID-19 and its association with clinical features and severity of the disease. Scand J Clin Lab Investig. 2021;81(2):160–5.
doi: 10.1080/00365513.2021.1871641
Beyerstedt S, Casaro EB, Rangel EB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905–19.
pubmed: 33389262
pmcid: 7778857
doi: 10.1007/s10096-020-04138-6
Pijls BG, Jolani S, Atherley A, Derckx RT, Dijkstra JIR, Franssen GHL, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11(1): e044640.
pubmed: 33431495
doi: 10.1136/bmjopen-2020-044640
Tepasse PR, Vollenberg R, Steinebrey N, Konig S. High angiotensin-converting enzyme and low carboxypeptidase N serum activity correlate with disease severity in COVID-19 patients. J Pers Med. 2022;12(3):406.
pubmed: 35330406
pmcid: 8949860
doi: 10.3390/jpm12030406